Flag of the European Union EU Clinical Trials Register Help

Clinical trials for roche OR chugai OR genentech

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,192 result(s) found for: roche OR chugai OR genentech. Displaying page 151 of 160.
    «« First « Previous 147  148  149  150  151  152  153  154  155  Next» Last»»
    EudraCT Number: 2010-023880-17 Sponsor Protocol Number: RR10/9589 Start Date*: 2011-03-31
    Sponsor Name:University of Leeds
    Full Title: SWITCH: Randomised-controlled trial of switching to alternative tumour-necrosis factor (TNF)-blocking drugs or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initia...
    Medical condition: Rheumatoid arthritis in patients who have failed to respond to an initial TNF-blocking drug
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-005104-25 Sponsor Protocol Number: INV500 Start Date*: 2018-01-02
    Sponsor Name:Nova BioPharma Limited
    Full Title: Relative bioavailability and comparative pharmacokinetics of 13-CRA oral liquid and extracted capsule formulations: a randomised, open label, multi-dose, cross-over clinical trial in patients requi...
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029205 - Nervous system disorders 10029212 Nervous system neoplasms malignant NEC HLT
    20.0 10029205 - Nervous system disorders 10029211 Nervous system neoplasms malignant and unspecified NEC HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-005247-10 Sponsor Protocol Number: ITCC-003-Tarceva/Roche MO 18461 Start Date*: 2005-07-29
    Sponsor Name:The University Hospitals of Leicester NHS Trust
    Full Title: Phase I study of TARCEVA (Erlotinib Hydrochloride, OSI-774) as a single agent in children with refractory and relapsed malignant brain tumours and in combination with irradiation in newly diagnosed...
    Medical condition: Refractory and relapsed malignant brain tumours and newly diagnosed brain stem glioma.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-005205-30 Sponsor Protocol Number: PM0259CA222B0 Start Date*: 2006-09-06
    Sponsor Name:Pierre Fabre Medicament
    Full Title: Randomised phase II study of the combination of oral vinorelbine with capecitabine versus a sequential regimen of oral vinorelbine and capecitabine versus the combination of docetaxel and capecitab...
    Medical condition: Patients with metastatic breast cancer previously treated with anthracyclines
    Disease: Version SOC Term Classification Code Term Level
    7.1 10027475 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015740-42 Sponsor Protocol Number: UKER00109STUM3 Start Date*: 2010-05-12
    Sponsor Name:Universitätsklinkum Erlangen
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, OPEN, PROSPECTIVE, CONTROLLED, PARALLEL-GROUP STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSION RETRO – REduction of Ther...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016862-10 Sponsor Protocol Number: XL147-203 Start Date*: 2010-06-22
    Sponsor Name:Exelixis INC.
    Full Title: A Phase 1/2 Study of XL147 Administered in Combination with Trastuzumab or Paclitaxel and Trastuzumab in Subjects with Metastatic Breast Cancer who have Progressed on a Previous Trastuzumab- Based ...
    Medical condition: Subjects with Metastatic Breast Cancer who have Progressed on a Previous Trastuzumab-Based Regimen
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003024-31 Sponsor Protocol Number: DAA-HCV Start Date*: 2015-11-06
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA
    Full Title: Anti-viral responses in patients with chronic HCV infection treated with DAA alone or with PEG-IFN based regimens
    Medical condition: CHRONIC HEPATITIS C
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003089-11 Sponsor Protocol Number: ICI21/00042 Start Date*: 2022-03-08
    Sponsor Name:Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC)
    Full Title: Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients: a Spanish Multicenter, Randomized, Controlled Parallel-group Trial: The TRAINING Study
    Medical condition: Subclinical inflammation, including borderline lesions (BL), is very common after kidney transplantation (KT), even in low immunological risk patients, and can lead to interstitial fibrosis/tubular...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004870 10018650 Graft rejection LLT
    21.1 100000004870 10049581 Graft rejection episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004014-17 Sponsor Protocol Number: FIL_GA101_DHAP Start Date*: 2014-08-04
    Sponsor Name:Fondazione Italiana Linfomi ONLUS
    Full Title: Phase II study with Ga101-DHAP as induction therapy in relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) patients before High-Dose chemotherapy BEAM with autologous stem cell transplantatio...
    Medical condition: Young patients with DLBCL who failed or relapsed after one previous chemotherapy regimen.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013766-78 Sponsor Protocol Number: CA191-004 Start Date*: 2010-04-14
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase I/II Trial of BMS-754807 in Combination with Trastuzumab (Herceptin®) in Subjects with Advanced or Metastatic Her-2-positive Breast Cancer Revised Protocol Number 01 (version 2.0, dated 0...
    Medical condition: Advanced or Metastatic Her-2-positive Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10065430 HER-2 positive breast cancer LLT
    12.0 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-008210-38 Sponsor Protocol Number: 2008_02/0841 Start Date*: 2009-04-16
    Sponsor Name:Chru de Lille
    Full Title: Effet d’un traitement anti-glutamatergique sur les troubles de la marche avec freezing et sur l’attention dans la maladie de Parkinson: “freezing of gait and glutamate: FOGG-I”
    Medical condition: Patients ayant une maladie de Parkinson Patients à un stade évolué de la maladie avec des troubles de la marche sévères
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    9.1 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014616-36 Sponsor Protocol Number: ANRS148 Start Date*: 2009-11-19
    Sponsor Name:Agence nationale de recherches sur le sida et les hépatites virales. ANRS.
    Full Title: Etude pilote de la pharmacocinétique, de la tolérance et de l’efficacité du raltégravir associé à deux molécules actives parmi les analogues nucléosi(ti)diques et l’enfuvirtide, avant et après tran...
    Medical condition: Période 1 : Hepatic insufficiency Période 2 Liver transplantation chez les patients infectés par le VIH-1
    Disease: Version SOC Term Classification Code Term Level
    12.0 10056542 LLT
    12.0 10024716 LLT
    12.0 10020161 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004423-78 Sponsor Protocol Number: SIR-POSA Start Date*: 2018-03-27
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A phase II trial of allogeneic peripheral blood stem cell transplantation from family haploidentical donors in patients with myelodisplastic syndrome and acute leukemia under primary antifungal pro...
    Medical condition: Myelodisplastic Syndrome (MDS) and Acute Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028532 Myelodysplasia LLT
    21.0 100000004864 10024289 Leukaemia acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004438-40 Sponsor Protocol Number: GI1950 Start Date*: 2020-04-06
    Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital
    Full Title: Phase 2 study in pretreated patients with advanced pancreatic cancer to assess efficacy of ipilimumab, nivolumab and tocilizumab in combination with radiation.
    Medical condition: Pretreated patients with advanced pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    21.0 100000004864 10033607 Pancreatic cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012942-22 Sponsor Protocol Number: PRODIGE 18 - ACCORD 22/0906 Start Date*: 2010-08-30
    Sponsor Name:Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
    Full Title: Essai de phase II, randomisé multicentrique, évaluant l'efficacité d'une chimiothérapie standard à base de fluoropyrimidine associée au cétuximab ou au bévacizumab, chez des patients kras sauvage, ...
    Medical condition: Cancer colorectal métastatique (CCM), KRAS sauvage, nécessitant un traitement de 2éme ligne.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10055114 Colon cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003795-49 Sponsor Protocol Number: IFCT-1603 Start Date*: 2016-12-16
    Sponsor Name:IFCT
    Full Title: A randomized multicenter, open label, controlled and non-comparative phase II study of anti–PDL1 ATEZOLIZUMAB (MPDL3280A) or chemotherapy as second-line therapy in patients with small cell lung can...
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041069 Small cell lung cancer limited stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-004455-17 Sponsor Protocol Number: ESR-20-21103 Start Date*: 2023-05-24
    Sponsor Name:VHIO Vall d’Hebron Institute of Oncology
    Full Title: Non‐Randomized, Open‐Label, Prospective Phase II Trial to Better Characterize the Status of HRD leading to a Benefit from Olaparib in Combination with Bevacizumab in Patients with Advanced FIGO Sta...
    Medical condition: Patients with Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer After Standard First‐Line Treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003976-11 Sponsor Protocol Number: HSG-1-13 Start Date*: 2014-01-24
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Effects of S-1 and capecitabine in combination with oxaliplatin on the coronary artery blood flow in patients metastatic gastrointestinal tract adenocarcinoma
    Medical condition: Metastatic gastrointestinal tract adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004171-36 Sponsor Protocol Number: S101-RGL-003 Start Date*: 2012-03-30
    Sponsor Name:Samsung Electronics Co. Ltd.
    Full Title: A Randomized, Double-blind, Parallel Group, Multicenter Trial to Compare the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of SAIT101 to MabThera® in Subjects with Severe Rheumatoid Arthr...
    Medical condition: Severe Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003295-12 Sponsor Protocol Number: 15022013 Start Date*: 2013-10-31
    Sponsor Name:Roskilde University Hospital
    Full Title: Combination Therapy Interferon Alpha + JAK1-2 Inhibitor in The Ph-Negative Chronic Myeloid Neoplasms
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10028538 Myelofibrosis with myelometaplasia LLT
    18.1 100000004864 10036061 Polycythemia vera LLT
    18.1 100000004864 10053134 Osteomyelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 147  148  149  150  151  152  153  154  155  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Feb 15 14:31:02 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA